<!-- PageNumber="291" -->
<!-- PageHeader="Protein kinase C in melanoma" -->

Table 2. (Continued)

| Cell line | PKC isoform | | | | | | | | | Detection* | Reference |
|-----------|-------------|---|---|---|---|---|---|---|---|------------|-----------|
|           | $$\alpha$$  | $$\beta I / \beta \Pi$$ | $$\gamma$$ | $$\delta$$ | $$\varepsilon$$ | $$\eta$$ | $$\theta$$ | $$\zeta$$ | $$\lambda/\iota$$ | | |
|-----------|-------------|------------------------|-----------|-----------|--------------|-----------|-----------|-----------|----------------|------------|-----------|
| WM115 (primary) | + | ND | ND | ND | ND | ND | ND | ND | ND | W | [36] |
| WM1205Lu (metastatic) | + | ND | ND | ND | ND | ND | ND | ND | ND | W | [36] |
| SK-Mel 28 (metastatic) | + | - | - | + | + | ND | + | + | ND | W, R | [29] |
| A375 (primary) | + | - | - | + | + | ND | + | + | ND | W, R | [29] |
| Murine | | | | | | | | | | | |
| B16 (metastatic) | + | - | + | ND | ND | ND | ND | ND | ND | N | [37] |
| B16-F1 (metastatic) | + | ND | ND | ND | ND | ND | ND | ND | ND | W | [38] |
| B16 (metastatic) | + | - | - | + | + | ND | ND | + | ND | N | [39] |
| B16 (metastatic) | + | - | - | - | - | ND | ND | + | ND | W | [30] |
| B16 (metastatic) | + | ND | ND | ND | ND | ND | ND | ND | ND | W | [40] |
| B16 (metastatic) | + | - | - | - | + | + | + | ND | + | W | [41] |
| B16 (metastatic) | + | ND | ND | ND | ND | ND | ND | ND | ND | W | [42] |
| B16 (metastatic) | + | + | + | + | + | + | + | ND | ND | W | [43] |
| B16 (metastatic) | + | - | - | + | + | - | ND | + | ND | W | [44] |
| B16-BL6 (metastatic) | + | ND | ND | ND | + | ND | ND | ND | ND | W | [45] |
| B16-BL6 (metastatic) | ND | ND | ND | - | ND | ND | ND | ND | ND | W | [46] |

\* N: Northern blot, F: Flow cytometry, W: Western blot, R: Reverse transcription-polymerase chain reaction.

** Not determined.

The $\beta$ isoform in melanocytes [49], and further showed that PKC inhibitor reduces pigmentation in murine skin in vivo [50]. It is interesting to assume that the $\beta$ isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC $\beta$ isoform [25,27]. On the other hand, the $\alpha$ isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,39], and the induction as well as the overexpression of this PKC isoform enhances the melanin synthesis, suggesting the involvement of the $\alpha$ isoform in melanogenesis [38]. The level of the $\alpha$ isoform is also elevated in B16 cells cultured with mannosylerythritol lipid, a novel extracellular glycolipid from yeast that induces differentiation of HL-60 promyelocytic leukemia cells [44]. The introduction of antisense oligodeoxynucleotides against the $\alpha$ isoform prevented mannosylerythritol lipid-induced melanogenesis, and the expression of the

Table 3. The expression of PKC isoforms in human melanoma cells in vivo

| Origin | PKC isoform | | | | | | | | | $$\lambda/\iota$$ | Detection** | Reference |
|--------|-------------|---|---|---|---|---|---|---|---|----------------|------------|-----------|
|        | Clinical type* | $$\alpha$$ | $$\beta \mathrm{I} / \beta \Pi$$ | $$\gamma$$ | $$\delta$$ | $$\varepsilon$$ | $$\eta$$ | $$\theta$$ | $$\zeta$$ | $$\lambda/\iota$$ | | |
|--------|-------------|---|---|---|---|---|---|---|---|----------------|------------|-----------|
| Primary | ALM | + | - | - | + | + | ND | ND | + | ND | W | [25] |
| Metastatic | Unknown | + | - | - | + | + | ND | ND | ND | ND | W | [25] |
| Metastatic | NS (5 cases) | ND | + | ND | ND | ND | ND | ND | ND | ND | I | [27] |
| Metastatic | NS (5 cases) | ND | - | ND | ND | ND | ND | ND | ND | ND | I | [27] |
| Metastatic | SSM | + | + | - | + | + | + | - | + | + | W | [28] |
| Metastatic | NS (5 cases) | + | + | - | + | + | + | - | + | + | W | [28] |
| Metastatic | ALM (2 cases) | + | + | - | + | + | + | - | + | + | W | [28] |
| Primary | ALM | - | ND | ND | ND | ND | ND | ND | ND | ND | I | [36] |
| Primary | ALM (11 cases) | + | ND | ND | ND | ND | ND | ND | ND | ND | I | [36] |
| Primary | SSM (7 cases) | + | ND | ND | ND | ND | ND | ND | ND | ND | I | [36] |
| Metastatic | ALM (2 cases) | + | ND | ND | ND | ND | ND | ND | ND | ND | I | [36] |
| Metastatic | SSM (2 cases) | + | ND | ND | ND | ND | ND | ND | ND | ND | I | [36] |

*ALM: acral lentiginous melanoma; SSM: superficial spreading melanoma; NS: not stated.

**W: Western blot, I: immunohistochemistry.

***Not determined.